Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

Go back to Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) Delayed: 32.37 --0 (-0%)
Previous Close $32.37    52 Week High $5.17 
Open $32.37    52 Week Low $0.94 
Day High $32.37    P/E N/A 
Day Low $32.37    EPS $0.00 
Volume 5,814